Table 1 Cell cycle analysis: Alternating treatment with sorafenib and lenvatinib SoLAT showed significant increase in the sub-G0/G1 population and induction of cell death in advanced PTC (GSP2 and GSP3)
Status | Sub-G0G1 | G0G1 | S | G2/M | |
|---|---|---|---|---|---|
GSP2 | |||||
Control | 1.4 ± 0.05 | 49.5 ± 0.05 | 27.2 ± 0.09 | 21.9 ± 0.05 | |
Sorafenib only | 4.7 ± 0.08 | 51.3 ± 0.07 | 25.4 ± 0.09 | 18.6 ± 0.05 | |
Lenvatinib only | 9.8 ± 0.04 | 49.6 ± 0.03 | 27.4 ± 0.12 | 13.2 ± 0.04 | |
SoLAT | S + L | 29.8 ± 0.09 | 46.7 ± 0.15 | 18.9 ± 0.05 | 4.6 ± 0.03 |
Sorafenib | 7.5 ± 0.02 | 49.5 ± 0.07 | 30.6 ± 0.01 | 12.4 ± 0.08 | |
Lenvatinib | 21.9 ± 0.04 | 50.1 ± 0.12 | 22.3 ± 0.05 | 5.7 ± 0.02 | |
Sorafenib | 1.7 ± 0.07 | 49.3 ± 0.04 | 28.5 ± 0.05 | 20.5 ± 0.09 | |
Lenvatinib | 13.7 ± 0.15 | 48.3 ± 0.02 | 27.5 ± 0.01 | 10.5 ± 0.02 | |
GSP3 | |||||
Control | 1.1 ± 0.03 | 49.8 ± 0.08 | 27.5 ± 0.15 | 21.6 ± 0.12 | |
Sorafenib only | 2.4 ± 0.04 | 51.6 ± 0.06 | 26.4 ± 0.05 | 19.6 ± 0.01 | |
Lenvatinib only | 13.6 ± 0.04 | 53.2 ± 0.03 | 24.5 ± 0.07 | 8.7 ± 0.05 | |
SoLAT | S + L | 36.2 ± 0.15 | 45.6 ± 0.14 | 14.3 ± 0.19 | 3.9 ± 0.22 |
Sorafenib | 2.7 ± 0.15 | 51.2 ± 0.12 | 26.7 ± 0.12 | 19.4 ± 17 | |
Lenvatinib | 32.4 ± 0.11 | 49.5 ± 0.21 | 13.5 ± 0.07 | 4.6 ± 0.15 | |
Sorafenib | 2.4 ± 0.15 | 52.8 ± 0.25 | 27.6 ± 0.14 | 17.2 ± 0.13 | |
Lenvatinib | 22.9 ± 0.24 | 55.1 ± 0.13 | 15.5 ± 0.19 | 6.5 ± 0.15 | |